http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
IsoRay, Inc. Announces Annual Meeting and Shareholder Record Dates
-
IsoRay (ISR) Appoints Two New Marketing Execs
-
IsoRay Appoints Michael L. Krachon as Vice President of Sales and Marketing and Lori A. Woods as Senior Marketing Consultant
-
IsoRay (ISR) Names New CEO
-
IsoRay Appoints Thomas LaVoy as CEO to Take Office on February 15
-
IsoRay (ISR) Announces Publication of Peer-Reviewed Study on Cesuim-131 Cost Effectiveness
-
Clinical Study Discusses Cost Effectiveness of Surgical Resection and IsoRay's Cesium-131 Intraoperative Brachytherapy
-
IsoRay (ISR) CEO Dwight Babcock to Retire
-
IsoRay Chairman and CEO Dwight Babcock to Retire
-
IsoRay (ISR) Announces Publication of Cesium-131 Brachytherapy in Brain Metastases Study
-
Weill Cornell Medical Clinical Study Demonstrates Cesium-131 Brachytherapy Seeds on a String Surgical Technique Promotes Dose Homogeneity and Minimizes the Risk of Radiation-Induced Injury
-
IsoRay (ISR) Announced Recent Publication of Peer-Reviewed Results of Study Using Cesium-131 Brachytherapy
-
Weill Cornell Clinical Study Notes Cesium-131 Brachytherapy Can Provide a Viable Alternative to Whole Brain Radiotherapy With Excellent Response Rates and Minimal Toxicity
-
IsoRay's Proprietary Cesium-131 Product Line Will Be on Display at the American Society for Radiation Oncology (ASTRO) Convention
-
Isoray, Inc. Announces Appointment of PCG Advisory Group as Investor, Public and Digital Communications Agency of Record
-
IMPORTANT INVESTOR ALERT: Goldberg Law PC Reminds Investors With Losses in IsoRay, Inc. of July 21, 2015 Deadline
-
IsoRay's Cesium-131 Cancer Fighting Portfolio was on Display at the American Association of Physicists in Medicine (AAPM) Convention
-
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against IsoRay, Inc. And Advises Shareholders To Contact The Firm Prior To The Lead Plaintiff Deadline
-
IsoRay's Cesium-131 Selected by Chicago Prostate Cancer Center for Use in the Launch of a Study of the Focal Treatment of Prostate Cancer
-
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against IsoRay, Inc. on Behalf of Investors
-
IsoRay Intends to Vigorously Defend Litigation
-
IsoRay Announces Appointment of New Director
-
IsoRay's Quality Management System Granted Continued Certification to Highest ISO Standard for Medical Device Manufacturers
-
IsoRay's Intra-Cranial Brachytherapy Brain Cancer Treatments Utilizing Cesium-131 Were Presented at the Brain Tumor Biotech Summit 2015
-
IsoRay (ISR) Criticized for Overly Promotional Press Releases
-
IsoRay's Cesium-131 Lung Cancer Treatment Reports 96% Success in Local Control and 100% Survival at 5 Years in High Risk Patients in Newly Published Report
-
IsoRay, Inc. Reports Third Quarter Results
-
IsoRay's Cesium-131 Cancer Treatment Takes Center Stage at Weill Cornell's International Symposium "Advances in Brachytherapy"
-
Thomas Jefferson University Launches Major Head and Neck Cancer Study Utilizing Cesium-131 Where Current Standard of Care Treatments Have Failed
-
IsoRay's Cancer Fighting Isotope Cesium-131 Will Be Featured in Four Oral Presentations at the American Brachytherapy Society (ABS) Convention in Orlando, Florida
-
Gynecologic Cancers Successfully Treated Using IsoRay's Cesium-131 Will Be Presented by Dr. Jonathan Feddock Saturday Night While at the Society of Gynecologic Oncology Convention (SGO)

